Floatz logo

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER

Psoriasis

Amgenprotein_peptidePhase 4 / ApprovedDormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Psoriasis cohort.

Asset / SponsorPhaseRating
Calcipotriene
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
Tirzepatide
Eli Lilly and Company
Phase 4BBB
Semaglutide
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
cp-690,550
Pfizer
Phase 3BBB
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL17A (INTERLEUKIN 17A, IL-17A)), HOMO SAPIENS MONOCLONAL ANTIBODY
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BB

View all 28 →

Same molecule, other indications

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:

Pancreatitis, Chronic; Diabetes; TransplantDormant
BB
Indicative ·
68 / 100
View asset →
skin carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
sciaticaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →